X4 Pharmaceuticals, Inc
For the period ended Mar 25, 2025. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 25, 2025 · Filed Mar 25, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Strategic Restructuring
Strategic Restructuring
In February 2025, X4 announced a strategic restructuring to sharpen focus and maximize the opportunity for mavorixafor in chronic neutropenia. Related activities included reducing overall headcount, discontinuing research efforts, pausing pre-clinical drug candidate programs, and closing the company’s facility in Vienna, Austria, as well as right-sizing its U.S. commercial field team and streamlining other spending. X4 continues to expect that these efforts will decrease spending by $30-35 million annually.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.